Choi H K, Merkel P A, Walker A M, Niles J L
Arthritis Unit, Massachusetts General Hospital, Boston, MA 02114, USA.
Arthritis Rheum. 2000 Feb;43(2):405-13. doi: 10.1002/1529-0131(200002)43:2<405::AID-ANR22>3.0.CO;2-5.
The triggers that induce antineutrophil cytoplasmic antibody (ANCA)-positive vasculitis (APV) are largely unknown. However, there have been reports suggesting that hydralazine, propylthiouracil, and several other drugs may cause some cases of APV, and the majority of these cases have been associated with antimyeloperoxidase (anti-MPO) ANCA. Our experience led us to hypothesize that cases of high titers of anti-MPO antibodies are often drug-associated.
In this study, we determined the prevalence of exposure to hydralazine, propylthiouracil, and other drugs previously implicated in APV among 30 patients with vasculitis and the highest titers of anti-MPO antibodies newly detected in our laboratory between 1994 and 1998. The clinical, histologic, and other serologic features of these 30 patients were also examined.
The 30 study patients accounted for 12% of the 250 new patients with APV and anti-MPO who were tested during the study period. All 30 study subjects had anti-MPO titers that were more than 12 times the median titer of the 250 patients. Ten (33%) of the 30 patients had been exposed to hydralazine and 3 (10%) had been exposed to propylthiouracil. An additional 5 patients (17%) had been exposed to 1 of the other previously reported candidate drugs: 2 to penicillamine, 2 to allopurinol, and 1 to sulfasalazine. One of the patients exposed to hydralazine had also been exposed to allopurinol. In all cases, the clinical and histologic findings were typical of APV. There was a strong association between the presence of antielastase and/ or antilactoferrin antibodies and exposure to candidate drugs.
These data suggest that a sizable proportion of cases of APV with high titers of anti-MPO antibodies are drug-associated, especially following exposure to hydralazine or propylthiouracil. We recommend that the use of these drugs should be sought in cases of anti-MPO-positive vasculitis, particularly among patients with high titers of these antibodies.
诱发抗中性粒细胞胞浆抗体(ANCA)阳性血管炎(APV)的触发因素在很大程度上尚不清楚。然而,有报告表明,肼屈嗪、丙硫氧嘧啶和其他几种药物可能导致一些APV病例,且这些病例大多数与抗髓过氧化物酶(抗MPO)ANCA相关。我们的经验使我们推测,高滴度抗MPO抗体的病例通常与药物有关。
在本研究中,我们确定了1994年至1998年间在我们实验室新检测出的30例血管炎患者且抗MPO抗体滴度最高者中,接触过肼屈嗪、丙硫氧嘧啶及其他先前认为与APV有关的药物的情况。还检查了这30例患者的临床、组织学及其他血清学特征。
这30例研究患者占研究期间检测的250例新的APV合并抗MPO患者的12%。所有30例研究对象的抗MPO滴度均超过250例患者中位数滴度的12倍。30例患者中有10例(33%)接触过肼屈嗪,3例(10%)接触过丙硫氧嘧啶。另外5例患者(17%)接触过其他先前报告的候选药物中的一种:2例接触青霉胺,2例接触别嘌醇,1例接触柳氮磺胺吡啶。1例接触肼屈嗪的患者也接触过别嘌醇。在所有病例中,临床和组织学表现均为典型的APV。抗弹性蛋白酶和/或抗乳铁蛋白抗体的存在与接触候选药物之间存在密切关联。
这些数据表明,相当一部分高滴度抗MPO抗体的APV病例与药物有关,尤其是在接触肼屈嗪或丙硫氧嘧啶之后。我们建议,对于抗MPO阳性血管炎病例,尤其是这些抗体滴度高的患者,应排查这些药物的使用情况。